Research Topics
Species | C BokemeyerSummaryCountry: Germany Publications
| Collaborators
|
Detail Information
Publications
Clinical impact of germ cell tumor cells in apheresis products of patients receiving high-dose chemotherapyC Bokemeyer
Department of Hematology Oncology, University of Tuebingen, Tuebingen
J Clin Oncol 19:3029-36. 2001..This study analyzed the presence and the clinical importance of contaminating tumor cells in PBSC preparations used to support HD-Ctx in GCT patients...
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trialsC Bokemeyer
Department of Hematology Oncology, University of Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
Br J Cancer 91:683-7. 2004..In conclusion, carboplatin single agent therapy cannot be recommended as standard treatment for any patient subgroup with advanced metastatic seminoma and cisplatin-based combination regimens remain the standard of care...
Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysisCarsten Bokemeyer
Tuebingen University Medical Center II, Tuebingen, Germany
J Clin Oncol 20:1864-73. 2002..To characterize the clinical and biologic features of extragonadal germ cell tumor (EGCT) and to determine the overall outcome with currently available treatment strategies...
Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapyC Bokemeyer
Abteilung Hamatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Germany
Onkologie 25:32-9. 2002....
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancerC Bokemeyer
Universitaetsklinikum Tuebingen, Medizinische Klinik Abteilung II, Otfried Mueller St 10, D 72076 Tuebingen, Germany
Eur J Cancer 40:2201-16. 2004..Additional trials are warranted, especially on the issues of iron replacement and cost-effectiveness of erythropoietic protein therapy, as well as on tumour response/progression and survival...
Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PETC Bokemeyer
Department of Hematology Oncology, University of Tuebingen Medical Center, Otfried Mueller Str 10, 72076 Tuebingen, Germany
Br J Cancer 86:506-11. 2002..It may also be a valuable addition to the prognostic model particularly in the good and intermediate group for further selection of patients who will profit from high-dose chemotherapy...
Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancerC Bokemeyer
Department of Haematology Oncology, University of Tuebingen Medical Centre, Otfried Muller Strasse 10, 72076 Tuebingen, Germany
Br J Cancer 87:1066-71. 2002..Despite the frequent use of red blood cell transfusions, median haemoglobin nadirs remained about 7.5-8 g dl(-1) during therapy. A correlation of haemoglobin-values after completion of therapy to overall treatment outcome was found...
Extragonadal germ cell tumors: relation to testicular neoplasia and management optionsCarsten Bokemeyer
Tuebingen University Medical Center II, Tuebingen, Germany
APMIS 111:49-59; discussion 59-63. 2003..Patients with mediastinal nonseminomas have a five-years survival rate of 45%. This outcome is clearly inferior compared to patients with nonseminomatous retroperitoneal primaries who have a five-year survival rate of 62%...
[Chemotherapy of advanced colorectal carcinoma: treatment options for elderly patients]C Bokemeyer
Abt für Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Universitatsklinikum Tuebingen
Onkologie 26:48-53. 2003..Future trials need to further redefine treatment strategies in elderly patients with colorectal cancer...
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancerC Bokemeyer
Department of Hematology Oncology, Internal Medicine II, Eberhard Karls University, Tubingen, Germany
J Clin Oncol 17:512-6. 1999..This phase II study evaluates the use of gemcitabine in patients with intensively pretreated or cisplatin-refractory testicular germ cell cancers...
Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG)C Bokemeyer
Department of Internal Medicine, University of Tuebingen Medical Center, Germany
Int J Cancer 83:848-51. 1999..Future trials combining new active agents may examine alternating treatment strategies in patients with poor-prognostic disease or as salvage treatment...
Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer SH J Schmoll
Department of Hematology Oncology, University of Halle, Halle, Germany
J Clin Oncol 21:4083-91. 2003..This analysis reports toxicity and long-term results of a large phase I/II study of sequential high-dose etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced germ cell tumors...
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancerJ Wierecky
Department of Oncology, Hematology, Immunology, and Rheumatology, Medizinische Klinik, University of Tuebingen Medical Center, Otfried-Mueller-Strasse 10, 72076 Tuebingen, Germany
J Cancer Res Clin Oncol 131:255-60. 2005..No solid tumors had occurred.CONCLUSIONS: HDCT including high-dose etoposide with autologous PBSCT as first-line therapy for advanced testicular cancer was associated with an acceptably low risk of developing secondary leukemia...
Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACOC Kollmannsberger
Department of Hematology/Oncology, Department of Radiation Oncology, University of Tuebingen, Tuebingen
Ann Oncol 16:1326-33. 2005..Treatment should be given in experienced centres in order to avoid unnecessary toxicity...
Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysisJ T Hartmann
Tuebingen University Medical Center II, Tuebingen, Germany
J Clin Oncol 19:1641-8. 2001....
Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcomeC Bokemeyer
Tuebingen University Medical Center II, Tuebingen, Germany
Cancer 91:1394-401. 2001..Primary radiotherapy seems to be associated with a significantly higher rate of disease recurrence, although most patients will be salvaged by subsequent chemotherapy...
Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell supportC Kollmannsberger
Department of Hematology/Oncology, University of Tuebingen, Germany
Eur J Cancer 39:775-82. 2003..If feasible, complete surgical resection of residual tumours appears to be the most efficient treatment...
First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trialC Bokemeyer
Tuebingen University Medical Center II, Department of Hematology, Oncology, Rheumatology and Immunology, Eberhard Karls University, Otfried Mueller Str 10, 70276 Tuebingen, Germany
Br J Cancer 89:29-35. 2003..Compared to data of an international database analysis including 253 patients with mediastinal nonseminoma treated with conventional chemotherapy, the results may indicate that HD-VIP results in an approximately 15% survival improvement...
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancerC Kollmannsberger
Department of Hematology Oncology, University of Tuebingen Medical Center, Tuebingen, Germany
Br J Cancer 83:458-62. 2000..While the overall acceptable toxicity allows its use in the palliative setting, it may also be an attractive option to be tested for neoadjuvant or adjuvant treatment...
Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancerJ T Hartmann
Department of Hematology Oncology Immunology, Eberhard Karls University Medical Center II, Tubingen, Germany
Anticancer Drugs 10:729-33. 1999..Mitomycin C demonstrates single-agent activity in pretreated gastric cancer, but has only limited efficacy following cisplatin/paclitaxel-based first-line chemotherapy...
Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinomaJ T Hartmann
Department of Hematology, Oncology and Immunology, Eberhard Karls University, UKT Medical Center II, Tubingen, Germany
Anticancer Res 20:1177-82. 2000..Mitomycin C has some single-agent activity in advanced gastric cancer but no substantial efficacy was seen as in heavily pretreated colorectal carcinoma...
Prognostic variables for response and outcome in patients with extragonadal germ-cell tumorsJ T Hartmann
Tuebingen University Medical Center II, Tuebingen, Germany
Ann Oncol 13:1017-28. 2002..This investigation evaluates prognostic variables in patients with seminomatous and non-seminomatous extragonadal germ-cell tumors (EGCT) in order to identify relevant factors for long-term outcome following cisplatin-based chemotherapy...
Treatment of brain metastases in patients with testicular cancerC Bokemeyer
Department of Hematology Oncology, Hannover University Medical School, Germany
J Clin Oncol 15:1449-54. 1997..This report summarizes the long-term results in 44 patients with brain metastases from testicular cancer treated between 1978 and 1995 at Hannover University Medical School...
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study GroupC Kollmannsberger
Department of Hematology/Oncology, University of Tuebingen Medical Center, Otfried-Mueller-Strasse 10, 72076 Tuebingen, Germany
J Clin Oncol 22:108-14. 2004....
Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphomaH Dittmann
Department of Nuclear Medicine, University of Tuebingen, Tuebingen, Germany
Oncol Rep 8:1393-9. 2001..In patients with suspected relapse of HD, FDG-PET seems not to offer any information over CT scans. Using SUVs is not superior to visual assessment of PET alone...
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study GroupC Kollmannsberger
Department of Haematology Oncology, University of Tuebingen Medical Center, Germany
Br J Cancer 87:729-32. 2002..Irinotecan at a dose of 300-350 mg m(-2) every 3 weeks appears to have no antitumour activity in patients with cisplatin-refractory germ cell cancer and, thus, further investigation in this disease is not justified...
Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study GroupC Kollmannsberger
Department of Hematology/Oncology, University of Tuebingen Medical Center, Tuebingen, Germany
J Clin Oncol 20:2031-7. 2002..Oxaliplatin may be a palliative treatment option for this patient population, and evaluation in combination regimens is warranted...
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)C Kollmannsberger
Department of Hematology/Oncology, University of Tuebingen, Germany
Ann Oncol 17:1007-13. 2006..CONCLUSIONS: Matuzumab doses up to 800 mg weekly with paclitaxel 175 mg/m(2) every 3 weeks are well tolerated, with no apparent drug interactions and with evidence of antitumor activity...
[Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?]F Honecker
Abteilunh Hämatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Tubingen
Onkologie 24:87-94. 2001..Further clinical trials of chemotherapy in elderly patients with colorectal cancer are necessary to gain information about treatment recommendations...
Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC)F Honecker
, Onkologie, Rheumatologie und Immunologie, , Germany
Onkologie 27:583-8. 2004..A review of the most important trials, assessing treatment options in elderly patients with lung cancer, either prospectively or retrospectively, is provided, and still unresolved issues are addressed...
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)H J Schmoll
European Germ Cell Cancer Consensus Group, Martin Luther University, Department of Hematology Oncology, Halle, Germany
Ann Oncol 15:1377-99. 2004..Since this guideline is based on the highest evidence level available today, a deviation from these proposals should be a rare and justified exception...
Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancerC Kollmannsberger
Department of Internal Medicine, University of Tuebingen Medical Center, Tuebingen, Germany
Cancer 95:301-8. 2002..The lack of differences between the tumors of refractory and the responsive patients indicates that overexpression of any of these receptor tyrosine kinases does not contribute to a resistant phenotype in GCTs...
[18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trialM de Wit
Department of Internal Medicine, University Clinic Hamburg Eppendorf, Berlin, Germany
Ann Oncol 19:1619-23. 2008....
Impact of tumor size on the long-term survival of patients with early stage renal cell cancerM Kuczyk
Department of Urology, Eberhard Karls University, Hoppe Seyler Strasse 3, 72076 Tubingen, Germany
World J Urol 23:50-4. 2005..The present study demonstrates the need for multivariate statistical approaches when the latest modification of the TNM classification system is critically evaluated...
Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapyC Kollmannsberger
Department of Medicine II, University of Tuebingen, Otfried-Mueller-Str. 10, 72076 Tuebingen, Germany
World J Urol 19:120-5. 2001..It is hoped that the increase in knowledge of the molecular mechanism of testicular cancer may lead to the development of new therapeutic options...
Evaluation of long-term toxicity after chemotherapy for testicular cancerC Bokemeyer
Department of Hematology Oncology, Hannover University Medical School, Germany
J Clin Oncol 14:2923-32. 1996..The influence of therapy and patient characteristics and the relationship between different toxicities are assessed...
Long-term effects on sexual function and fertility after treatment of testicular cancerJ T Hartmann
Department of Hematology Oncology Immunology Rheumatology, UKL Medical Center II, Eberhard Karls University, , Germany
Br J Cancer 80:801-7. 1999..Twenty-one of 40 patients were able to fulfil their wish for children, and no congenital abnormalities were observed in these children...
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcomaJ T Hartmann
Department of Medical Oncology, Hematology, Immunology, Rheumatology, Pneumology, South West German Cancer Center, Eberhard Karls University, Tuebingen, Germany
Invest New Drugs 24:249-53. 2006..The aim of this trial was to evaluate the efficacy of gemcitabine in this setting...
Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experienceM A Kuczyk
Department of Urology, Eberhard Karls University, Hoppe Seyler Str 3, 72076 Tubingen, Germany
World J Urol 22:55-9. 2004..It became evident that in selected cases chemotherapy alone can be considered a curative treatment option...
Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levelsM Horstmann
Department of Urology, Eberhard Karls University Tubingen, Hoppe Seyler Str 3, 72076, Tubingen, Germany
J Cancer Res Clin Oncol 131:715-22. 2005..The value of bFGF serum levels as indicators of systemic tumour dissemination remains to be determined...
Therapy-related malignancies following treatment of germ cell cancerC Kollmannsberger
Department of Medicine, University of Tuebingen, Germany
Int J Cancer 83:860-3. 1999..However, even the acceptably low number of therapy-related leukemias should encourage the search for equally effective but less toxic therapies...
Chemotherapy in elderly patients with advanced lung cancer. Part I: General aspects and treatment of small cell lung cancer (SCLC)F Honecker
, Onkologie, Rheumatologie und Immunologie, , Germany
Onkologie 27:500-5. 2004..Further evaluation of these topics is needed, and can be achieved by trials specifically designed for elderly patients or patients with reduced performance status...
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation studyJ T Hartmann
Abt Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Eberhard Karls Universitat, Tuebingen, Germany
Br J Cancer 89:2051-6. 2003..In gastric cancer,MMC plus infusional 5-FU/folinic acid may be a potential second-line regimen with promising antitumour activity...
Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomasJ T Hartmann
Tuebingen University Medical Center II, Tuebingen, Germany
Anticancer Res 23:1899-901. 2003..The number of cytostatic agents effective in patients with advanced soft tissue sarcoma is limited. Trofosfamide, an alkylating agent, has been shown to be effective in several solid and haematological tumors...
Platinum organ toxicity and possible prevention in patients with testicular cancerJ T Hartmann
Department of Hematology Oncology Immunology, UKT Medical Center II, Eberhard Karls University, Tuebingen, Germany
Int J Cancer 83:866-9. 1999..Several strategies have been developed to reduce such side effects. Ongoing trials are investigating the role of the aminothiol amifostine as a nephro- and neuroprotectant...
The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesnaC Bokemeyer
Department of Hematology Oncology, Hannover University Medical School, Germany
Br J Cancer 69:863-7. 1994..These results are most likely transferable to the use of mesna in patients with metastatic testicular cancer...
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumorsJ T Hartmann
Department of Hematology and Oncology, UKT Medical Center II, Eberhard Karls University, Tubingen, Germany
Anticancer Drugs 11:1-6. 2000..This dose of amifostine may be sufficient for nephroprotection in patients without pre-existing risk factors for renal damage who undergo a restricted number of chemotherapy cycles...
Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustineU Reichmann
Department of Radiooncology, University of Tuebingen, Tuebingen, Germany
Ann Oncol 18:1981-4. 2007..This multicenter phase II trial defines the toxicity and activity of bendamustine in heavily pretreated patients...
Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamideJ T Hartmann
Department of Hematology, Oncology, Immunology, UKT Medical Center II, University of Tubingen, Germany
Anticancer Res 20:3767-73. 2000..In the light of the long-term consequences of persistent renal damage prevention of nephrotoxicity should be further improved...
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumorsJ T Hartmann
Department of Hematology and Oncology, UKT Medical Center II, Eberhard Karls University of Tubingen, Germany
Invest New Drugs 18:281-9. 2000..This may be advantageous if repetitive cycles of chemotherapy or subsequent administration of high dose chemotherapy is planned...
[Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker]A C Pfannenberg
Abteilung für Radiologische Diagnostik, Eberhard Karls Universität Tuebingen
Rofo 176:76-84. 2004..To assess the ability of [(18)F]FDG-PET, CT/MRI and serum tumor marker (TM) for the early prediction of response in patients with metastatic germ cell tumors (GCT) undergoing salvage high-dose chemotherapy (HD-CTX)...
Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumorsC Bokemeyer
Eberhard Karls Universitat Tubingen, Medizinische Klinik und Poliklinik, Deutschland
Oncology 55:177-88. 1998....
[Compression syndromes]J Wierecky
, Onkologie, Immunologie und Rheumatologie, Medizinische Klinik II,
Internist (Berl) 46:9-18. 2005..MRI should be preferred in the diagnostic work-up, corticosteroids be administered promptly after biopsy. Radiation therapy or surgical treatment should be started as soon as possible...
Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelinesMichael Heuser
Department of Hematology, Hemostaseology, and Oncology, Hannover Medical School, Hannover, Germany
Semin Hematol 44:148-56. 2007..Strategies are being developed to tailor the use of CSFs to patients with a high risk of adverse outcome of FN...
Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study GroupAnja Lorch
Department of Hematology, Universitätsklinikum Giessen und Marburg GmbH, Marburg, Germany
J Clin Oncol 25:2778-84. 2007..To compare single versus sequential high-dose chemotherapy (HDCT) as first or subsequent salvage treatment in patients with relapsed or refractory germ cell tumors (GCTs)...
Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumorsSandra Mueller
Department of Oncology, Hematology, Immunology and Rheumatology, Medical Center, University of Tuebingen, Tuebingen, Germany
Invest New Drugs 25:519-24. 2007..However, possibly in view of their extensive telomere "reserve," telomerase inhibition did neither result in increased sensitivity of 2102 EP cells to cisplatin nor did co-treated cells show accelerated telomere shortening...
Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II studyJorg Thomas Hartmann
Abteilung Onkologie Hämatologie Immunologie Rheumatologie Pulmologie, Medizinische Klinik II, Eberhard Karls Universitat, Tubingen, Germany
Onkologie 30:235-40. 2007..To assess the toxicity and activity of bolus mitomycin C (MMC) in combination with a 24-hour continuous infusion of 5-fluorouracil (5-FU) in gastric cancer patients who had received at least one prior chemotherapy regimen...
A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC)Eckart Laack
University Hospital Hamburg Eppendorf, Hamburg, Germany
Lung Cancer 57:181-6. 2007..The aim of this phase II trial was to evaluate the efficacy and safety of a combination chemotherapy containing irinotecan (CPT-11) and carboplatin as first-line treatment of patients with small cell lung cancer (SCLC)...
The translocations t(6;18;11)(q24;q21;q21) and t(11;14;18)(q21;q32;q21) lead to a fusion of the API2 and MALT1 genes and occur in MALT lymphomasEva M Murga Penas
University Medical Center Hamburg Eppendorf, Hamburg, Germany
Haematologica 92:405-9. 2007..FISH revealed the involvement of the immunoglobulin locus in the t(11;14;18). Rapid amplification of cDNA ends (RACE)-PCR to detect the involved partner gene on 6q showed exclusively wild-type API2 and MALT1 sequences...
Lectin histochemistry of metastatic adenocarcinomas of the lungIna Thom
Department of Hematology, Oncology and Pneumology, University Hospital Hamburg Eppendorf, Germany
Lung Cancer 56:391-7. 2007..The aim of the present investigation was thus to analyse a possible association between the presence of lectin binding sites of pulmonary adenocarcinoma cells and their lymph node and haematogenous metastatic cells...
An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumorsKarin Oechsle
Department of Oncology Hematology Bone marrow transplantation Pneumology, University Medical Center, Eppendort, Hamburg, Germany
Anticancer Drugs 18:273-6. 2007..Capecitabine was well tolerated, but is not effective in heavily pretreated patients with cisplatin-refractory or relapsed germ cell tumors...
A case of pulmonary carcinosarcoma (squamous cell carcinoma and osteosarcoma) treated with cisplatin and doxorubicinFlorian Langer
II Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg, Germany
Anticancer Res 26:3893-7. 2006..Pulmonary carcinosarcoma is a rare malignancy composed of epithelial and mesenchymal elements. Little information is available on systemic treatment options for this tumor entity...
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study GroupMatthias Schwab
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Stuttgart, Stuttgart, Germany
J Clin Oncol 26:2131-8. 2008....
Platinum-based chemotherapy plus cetuximab in head and neck cancerJan B Vermorken
Antwerp University Hospital, Department of Medical Oncology, Edegem, Belgium
N Engl J Med 359:1116-27. 2008..We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck...
Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancerChristian Kollmannsberger
Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Curr Opin Support Palliat Care 2:167-72. 2008..This review summarizes the existing evidence including several recently published larger studies on the use of high-dose chemotherapy in these patients...
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische OnkologieSalah Eddin Al-Batran
Department of Hematology and Oncology, Krankenhaus Nordwest, Frankfurt, Germany
J Clin Oncol 26:1435-42. 2008..This study was designed to compare fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin in patients with advanced gastric cancer...
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh
Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany
Lancet Oncol 9:105-16. 2008..This randomised trial assessed whether six or eight cycles of R-CHOP-14 can improve outcome of these patients compared with six or eight cycles of CHOP-14...
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part ISusanne Krege
Department of Urology, Krankenhaus Maria Hilf, Krefeld, Germany
Eur Urol 53:478-96. 2008..In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands...
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part IISusanne Krege
Department of Urology, Krankenhaus Maria Hilf, Krefeld, Germany
Eur Urol 53:497-513. 2008..In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, The Netherlands...
Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study GroupJorg T Hartmann
Department of Oncology, South West German Comprehensive Cancer Center, Eberhard Karls University of Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
J Clin Oncol 25:5742-7. 2007....
Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancerChristian Peschel
Technische Universitat, III Medizinische Klinik, Munchen, Germany
Lung Cancer 60:374-80. 2008..v. infusion at a dose of 5mg/m(2), every 2 weeks, to patients with chemotherapy pretreated advanced non-small cell lung cancer (NSCLC)...
Germ-cell tumorsAnja Lorch
N Engl J Med 357:1772-3; author reply 1773-4. 2007
Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens?Carsten Bokemeyer
J Clin Oncol 26:1783-5. 2008
A pilot study of docetaxel and trofosfamide as second-line 'metronomic' chemotherapy in the treatment of metastatic non-small cell lung cancer (NSCLC)Michael Gorn
Department of Oncology, Hematology, Bone Marrow Transplantation with the Section of Pneumology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Onkologie 31:185-9. 2008..The aim of this pilot study was to evaluate the efficacy and safety of a chemotherapy containing docetaxel and oral trofosfamide as a 'metronomic' secondline treatment of patients with metastatic non-small cell lung cancer (NSCLC)...
Erythropoietins should be used according to guidelinesMatti S Aapro
Lancet Oncol 9:412-3. 2008
A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancerChristof Burkart
Departments of Medical Oncology, Hematology, Immunology, Rheumatology, Pulmology, Medical Center II, Tubingen, Germany
Anticancer Res 27:2845-8. 2007..This study investigated the efficacy and toxicity of weekly single-agent irinotecan in patients with metastatic disease relapsing after cisplatin-based chemotherapy...
Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO)Jorg Thomas Hartmann
Abteilung Onkologie Hämatologie Immunologie Rheumatologie Pulmologie, Südwestdeutsches Tumorzentrum Comprehensive Cancer Center Tübingen, Eberhard Karls Universitat Tubingen, Germany
Onkologie 31:237-41. 2008..The aim of the study was to establish the recommended dose and to evaluate the safety of gefitinib plus FUFOX regimen in irinotecan-refractory colorectal carcinoma (CRC)...
Renal toxicity of adjuvant chemoradiotherapy with cisplatin in gastric cancerStefan Welz
Heinrich Heine University of Dusseldorf, Dusseldorf, Germany
Int J Radiat Oncol Biol Phys 69:1429-35. 2007..On the basis of previously reported results of a Phase II trial using a more aggressive, cisplatin-containing chemoradiotherapy schedule, we investigated the effects of this approach on long-term renal function...
Safe use of oxaliplatin in a patient with metastatic breast cancer and combined renal and hepatic failureFriedemann U Honecker
Zentrum fur Innere Medizin, Medizinische Klinik und Poliklkinik, Universitatsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
Onkologie 29:273-5. 2006..No data is available regarding safety of oxaliplatin in patients with combined renal and hepatic dysfunction...
Long-term survival after second-line therapy with docetaxel and carboplatin and monthly pamidronic acid in a woman with metastatic non-small cell lung cancerBirte Andritzky
Department of Oncology and Hematology, University Hospital Hamburg Eppendorf, Germany
Onkologie 29:206-8. 2006..In patients with metastatic non-small cell lung cancer (NSCLC), second-line chemotherapy induces response rates of less than 20% and median survival times between 5 and 8 months...
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracilJoerg Thomas Hartmann
Abt Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Eberhard Karls Universitat, Tubingen, Germany Krankenhaus Nordwest, Frankfurt, Germany
Anticancer Drugs 15:473-7. 2004..Elderly patients had the same probability to respond...
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trialMaria De Santis
Department of Medical Oncology, Kaiser Franz Josef Spital, Kundratstrasse 3, A-1100 Wien, Austria
J Clin Oncol 22:1034-9. 2004..CONCLUSION: This investigation confirms that FDG PET is the best predictor of viable residual tumor in postchemotherapy seminoma residuals and should be used as a standard tool for clinical decision making in this patient group...
Is once-weekly epoetin beta 'highly effective' in treating anaemia in patients with lymphoproliferative malignancy?Carsten Bokemeyer
Br J Haematol 125:98-9; author reply 99-100. 2004
The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for managementAnna C Pfannenberg
Department of Diagnostic Radiology, Eberhard Karls University Tuebingen, Hoppe Seyler Strasse 3, 72076 Tuebingen, Germany
World J Urol 22:132-9. 2004..PET seems useful in patients with stable disease or partial remission in CT/MRI and normalized TM as well as in marker-negative disease...
Cost-utility analysis of survival with epoetin-alfa versus placebo in stage IV breast cancerSilas C Martin
Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, New Jersey, USA
Pharmacoeconomics 21:1153-69. 2003..Although the study was not designed or powered to evaluate survival, a survival trend was noted favouring epoetin-alfa compared with placebo (median survival 17 vs 11 months [p = 0.126])...
Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumorsFriedemann Honecker
Department of Pathology, Laboratory for Experimental Patho-Oncology, Josephine Nefkens Institute, Erasmus MC, University Medical Center Rotterdam, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Lab Invest 83:1489-95. 2003..We therefore conclude that XPA does not play a critical role in overall treatment resistance of GCTs...
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemiaTim H Brummendorf
Abteilung Hämatologie Onkologie, Medizinische Universitatsklinik, Tubingen, Germany
Ann N Y Acad Sci 996:26-38. 2003..05), interphase FISH (n = 204, p = 0.002), or quantitative RT-PCR (n = 371, p < 0.05). In conclusion, the increase in telomere length under treatment with imatinib reflects a shift from Ph+ to Ph- cells in the PB of patients with CML...
Treatment of lung cancer in elderly part II: small cell lung cancerMartin Weinmann
Department of Radiation Oncology, University of Tubingen, Hoppe Seyler Strasse 3, 72076, Tubingen, Germany
Lung Cancer 40:1-16. 2003..For the comparison of trials in elderly patients it will be of key importance to include a comprehensive and standardised geriatric assessment in such studies...
Colorectal cancer in the elderly: is palliative chemotherapy of value?Friedemann Honecker
Department of Hematology Oncology Immunology, University Medical Center II, Eberhard Karls Universitat, Tubingen, Federal Republic of Germany
Drugs Aging 20:1-11. 2003..Clearly, further clinical trials in elderly patients with colorectal cancer are necessary as well as the incorporation of aspects of geriatric medicine into the teaching programme of medical oncologists...
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemiaTim H Brummendorf
Blood 101:375-6. 2003
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissuesAxel S Merseburger
Department of Genitourinary Pathology, Armed Forces Institute of Pathology (AFIP, Washington, DC 20306-6000, USA
Oncol Rep 10:223-8. 2003..The TMA technique is probably more informative and reliable in evaluating the prognostic value of homogeneously expressed biomarkers...
Microsatellite instability of germ cell tumors is associated with resistance to systemic treatmentFrank Mayer
Pathology/Laboratory for Exp. Patho-Oncology, University Hospital Rotterdam/Daniel, Josephine Nefkens Institute, Erasmus University Rotterdam, 3000 DR Rotterdam, The Netherlands
Cancer Res 62:2758-60. 2002..001). In 5 of all 11 unstable tumors, MSI correlated with immunohistochemical findings. This study demonstrates for the first time a positive correlation between MSI and treatment resistance in GCT...
Anemia impact and management: focus on patient needs and the use of erythropoietic agentsCarsten Bokemeyer
Universitatsklinikum Tuebingen, Medizinische Klinik Abteilung, Germany
Semin Oncol 31:4-11. 2004..There is a strong need for increased awareness of cancer-related anemia and the consequences of its lack of treatment...
Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1Paul W Schenk
Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
Neoplasia 6:297-301. 2004..001). In conclusion, our data suggest that SRPK1 expression might be an important prognostic indicator for the chemoresponsiveness of nonseminomatous GCTs...
Recent advances in management of patients with platinum-refractory testicular germ cell tumorsChristian Kollmannsberger
Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia Vancouver Cancer Center, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada
Cancer 106:1217-26. 2006..This research may eventually allow the development of a noncross-resistant multidrug combination regimen that can be evaluated in an earlier line of therapy...
Guidelines on testicular cancerPeter Albers
Department of Urology, Klinikum Kassel GmbH Mönchebergstr 41 43, Kassel, Germany
Eur Urol 48:885-94. 2005..To up-date the 2001 version of the EAU testicular cancer guidelines...
Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumorsJorg Thomas Hartmann
Department of Hematology Oncology Immunology, UKT Medical Center II, Eberhard Karls University, Tubingen, Germany
Ann Surg 242:260-6. 2005..To evaluate the role of postchemotherapy adjunctive surgery in patients with liver metastases from germ cell cancer (GCT)...
Identification of germ cells at risk for neoplastic transformation in gonadoblastoma: an immunohistochemical study for OCT3/4 and TSPYAnne Marie F Kersemaekers
Department of Pathology, Josephine Nefkens Institute, Daniel de Hoed Cancer Center, Erasmus MC University Medical Center Rotterdam, The Netherlands
Hum Pathol 36:512-21. 2005..This could allow better prediction of the risk of progression to a GCT. In addition, the data support the model that GB represents the earliest accessible developmental stage of malignant GCTs...
Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell linesFrank Mayer
Department of Oncology, Hematology, Immunology, and Rheumatology, , Otfried-Mueller-Str. 10, , Germany
Invest New Drugs 23:205-11. 2005..No cross resistance between FP and cisplatin was observed. A clinical trial evaluating the activity of FP in patients with cisplatin-refractory GCTs appears to be warranted...
Cancer-related anemia: pathogenesis, prevalence and treatmentGunnar Birgegard
Department of Internal Medicine, University Hospital, Uppsala, Sweden
Oncology 68:3-11. 2005..These findings are noteworthy, since a growing body of clinical evidence indicates that the treatment of anemia can significantly improve patients' quality of life and may also improve the clinical outcome...
Telomere length and telomerase activity in the BCR-ABL-transformed murine Pro-B cell line BaF3 is unaffected by treatment with imatinibUlrike Hartmann
Department of Hematology and Oncology, , , Germany
Exp Hematol 33:542-9. 2005....
